11,11′-Dideoxy-verticillin: A natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity

Anti-Cancer Drugs

Volumn 16, Issue 5, 2005, Pages 515-524

  Zhang, Yi Xiang ^a,b   Chen, Yi ^a   Guo, Xiao Ning ^a,b   Zhang, Xiong Wen ^a   Zhao, Wei Min ^a   Zhong, Li ^a,b   Zhou, Jin ^a,b   Xi, Yong ^a   Lin, Li Ping ^a   Ding, Jian ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

11,11 dideoxy verticillin; Anti tumor; Epidermal growth factor receptor; Erk1 2; Vascular endothelial growth factor receptor 1

Indexed keywords

11,11' DIDEOXYVERTICILLIN; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATURAL PRODUCT; PIPERAZINEDIONE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; 11,11' DIDEOXYVERTICILIN; 11,11'-DIDEOXYVERTICILIN; ANTINEOPLASTIC AGENT; GROWTH FACTOR RECEPTOR; HERBACEOUS AGENT; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL FREE SYSTEM; CHINESE MEDICINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HERB; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; MOUSE; NICK END LABELING; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SARCOMA; SHIRAIA BAMBUSICOLA; WESTERN BLOTTING; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; LIVER TUMOR; MOUSE STRAIN; PHOSPHORYLATION; SARCOMA 180; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; SARCOMA 180;

EID: 21044436266     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200506000-00007     Document Type: Article

References (25)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
2. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-365.
3. Favoni RE, De Cupis A. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol Rev 2000; 52:179-206.
4. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002; 1:117-123.
5. Fabbro D, Parkinson D, Matter A. Protein tyrosine kinase inhibitors: new treatment modalities? Curr Opin Pharmacol 2002; 2:374-381.
6. Fischer OM, Streit S, Hart S, Ullrich A. Beyond Herceptin and Gleevec. Curr Opin Chem Biol 2003; 7:490-495.
7. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Ass 2003; 290:2149-2158.
8. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
9. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60:1383-1387.
10. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22:133-142.
11. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-1530.
12. Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 1999; 82:195-206.
13. Ben-Bassat H. Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy. Curr Opin Invest Drugs 2001; 2:1539-1545.
14. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994; 265:1093-1095.
15. Osherov N, Gazit A, Gilon C, Levitzki A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J Biol Chem 1993; 268:11134-11142.
16. Zhuang SF, Zhou CH, Qian J, Qian Z, Shibuya M, Ye QZ. A new model for random screening inhibitors of vascular endothelial growth factor receptor 1 kinase. Acta Pharmacol Sin 2002; 23:117-123.
17. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
18. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, et al. AEE788: a dual family epidermal growth factor receptor/ErbB-2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64: 4931-4941.
19. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
20. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000; 19:6594-6599.
21. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61: 7184-7188.
22. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376:66-70.
23. Pahl HL, Krauss B, Schulze-Osthoff K, Decker T, Traenckner EB, Vogt M, et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med 1996; 183:1829-1840.
24. Erkel G, Gehrt A, Anke T, Sterner O. Induction of differentiation in acute promyelocytic leukemia cells (HL-60) by the verticillin derivative Sch 52900. Z Naturforsch [C] 2002; 57:759-767.
25. Chai CL, Waring P. Redox sensitive epidithiodioxopiperazines in biological mechanisms of toxicity. Redox Rep 2000; 5:257-264.